Free Trial

Innoviva Q2 2024 Earnings Report

Innoviva logo
$17.79 -0.05 (-0.28%)
(As of 12/23/2024 05:26 PM ET)

Innoviva EPS Results

Actual EPS
$0.68
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$99.90 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q2 2024
Time
N/A
We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

Innoviva Earnings Headlines

Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA) engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

View Innoviva Profile

More Earnings Resources from MarketBeat